Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Pfizer, GlaxoSmithKline give timeline for IPO of joint venture Automation in action: Inside Priority Health’s operational overhaul Recommended Live Webinar on Jul 15, 2025 1:00 PM - 2:00 PM CDT ...

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion). British-based Glaxo ...

Glaxo and Pfizer each committed to supply 30 million doses of their Synflorix and Prevnar 13 vaccines to GAVI over 10 years, at $7 per dose for the first 20 percent supplied, dropping to $3.50 for ...

GlaxoSmithKline and Pfizer <PFE.N>, two leading developers of AIDS drugs, are merging their HIV operations into a new company that will hold nearly a fifth of the market for treatments ...